Information Provided By:
Fly News Breaks for February 14, 2019
ALKS
Feb 14, 2019 | 16:44 EDT
Piper Jaffray analyst Danielle Brill kept her Neutral rating and $32 price target on Alkermes after its Q4 results, saying that while revenue and earnings topped expectations, she wanted to see expectations of higher growth ahead. The analyst notes that the company's FY19 outlook implies revenue growth of 5%-9% and sees "meaningful impact from current pipeline" as unlikely. Brill adds that she is looking forward to Alkermes' launch of 3831 in schizophrenia by mid-2020, but sees limited potential for significant growth otherwise.
News For ALKS From the Last 2 Days
There are no results for your query ALKS